SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yibo Xue, Brian Meehan, Zheng Fu, Xue Qing D. Wang, Pierre Olivier Fiset, Ralf Rieker, Cameron Levins, Tim Kong, Xianbing Zhu, Geneviève Morin, Lashanda Skerritt, Esther Herpel, Sriram Venneti, Daniel Martinez, Alexander R. Judkins, Sungmi Jung, Sophie Camilleri-Broet, Anne V. Gonzalez, Marie-Christine Guiot, William W. Lockwood, Jonathan D. Spicer, Abbas Agaimy, William A. Pastor, Josée Dostie, Janusz Rak, William D. Foulkes, Sidong Huang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/f919a450f672493c812a00c6c5045ab6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f919a450f672493c812a00c6c5045ab6
record_format	dspace
spelling	oai:doaj.org-article:f919a450f672493c812a00c6c5045ab62021-12-02T17:02:16ZSMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer10.1038/s41467-019-08380-12041-1723https://doaj.org/article/f919a450f672493c812a00c6c5045ab62019-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-08380-1https://doaj.org/toc/2041-1723Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers to CDK4/6 inhibition.Yibo XueBrian MeehanZheng FuXue Qing D. WangPierre Olivier FisetRalf RiekerCameron LevinsTim KongXianbing ZhuGeneviève MorinLashanda SkerrittEsther HerpelSriram VennetiDaniel MartinezAlexander R. JudkinsSungmi JungSophie Camilleri-BroetAnne V. GonzalezMarie-Christine GuiotWilliam W. LockwoodJonathan D. SpicerAbbas AgaimyWilliam A. PastorJosée DostieJanusz RakWilliam D. FoulkesSidong HuangNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Yibo Xue Brian Meehan Zheng Fu Xue Qing D. Wang Pierre Olivier Fiset Ralf Rieker Cameron Levins Tim Kong Xianbing Zhu Geneviève Morin Lashanda Skerritt Esther Herpel Sriram Venneti Daniel Martinez Alexander R. Judkins Sungmi Jung Sophie Camilleri-Broet Anne V. Gonzalez Marie-Christine Guiot William W. Lockwood Jonathan D. Spicer Abbas Agaimy William A. Pastor Josée Dostie Janusz Rak William D. Foulkes Sidong Huang SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
description	Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers to CDK4/6 inhibition.
format	article
author	Yibo Xue Brian Meehan Zheng Fu Xue Qing D. Wang Pierre Olivier Fiset Ralf Rieker Cameron Levins Tim Kong Xianbing Zhu Geneviève Morin Lashanda Skerritt Esther Herpel Sriram Venneti Daniel Martinez Alexander R. Judkins Sungmi Jung Sophie Camilleri-Broet Anne V. Gonzalez Marie-Christine Guiot William W. Lockwood Jonathan D. Spicer Abbas Agaimy William A. Pastor Josée Dostie Janusz Rak William D. Foulkes Sidong Huang
author_facet	Yibo Xue Brian Meehan Zheng Fu Xue Qing D. Wang Pierre Olivier Fiset Ralf Rieker Cameron Levins Tim Kong Xianbing Zhu Geneviève Morin Lashanda Skerritt Esther Herpel Sriram Venneti Daniel Martinez Alexander R. Judkins Sungmi Jung Sophie Camilleri-Broet Anne V. Gonzalez Marie-Christine Guiot William W. Lockwood Jonathan D. Spicer Abbas Agaimy William A. Pastor Josée Dostie Janusz Rak William D. Foulkes Sidong Huang
author_sort	Yibo Xue
title	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
title_short	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
title_full	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
title_fullStr	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
title_full_unstemmed	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
title_sort	smarca4 loss is synthetic lethal with cdk4/6 inhibition in non-small cell lung cancer
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/f919a450f672493c812a00c6c5045ab6
work_keys_str_mv	AT yiboxue smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT brianmeehan smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT zhengfu smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT xueqingdwang smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT pierreolivierfiset smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT ralfrieker smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT cameronlevins smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT timkong smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT xianbingzhu smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT genevievemorin smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT lashandaskerritt smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT estherherpel smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT sriramvenneti smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT danielmartinez smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT alexanderrjudkins smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT sungmijung smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT sophiecamilleribroet smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT annevgonzalez smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT mariechristineguiot smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT williamwlockwood smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT jonathandspicer smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT abbasagaimy smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT williamapastor smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT joseedostie smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT januszrak smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT williamdfoulkes smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer AT sidonghuang smarca4lossissyntheticlethalwithcdk46inhibitioninnonsmallcelllungcancer
_version_	1718381944547311616

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

Ejemplares similares